Psychiatry and Neurology, Neurology · Sarasota, FL
NPI
1073624102
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
3
Medicare group memberships
Hospitals
2
Hospital affiliations
5741 Bee Ridge Rd Ste 530
Sarasota, FL, 34233
Phone (941) 487-2160
Groups this clinician bills Medicare through
Medicare paid, 2024
$178K
13,403 services
Medicare patients, 2024
577
Average age 74
Drug cost, 2024
$8.5M
3,896 prescriptions
Company payments, 2025
$236K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Donald Negroski was code J0585 (injection, onabotulinumtoxina, 1 unit), 12,225 times for 26 patients. In total Donald Negroski billed 13,403 services in 23 codes, and Medicare paid $178K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-02-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 12,225 | 26 | $4.89 | $60K |
| 99214 Office E&M - Established | Office | 544 | 376 | $88.90 | $48K |
| 95886 Electrical Nerve Conductivity | Office | 154 | 99 | $69.46 | $11K |
| 99213 Office E&M - Established | Office | 80 | 78 | $57.70 | $4,616 |
| 64615 Musculoskeletal | Office | 78 | 26 | $125.04 | $9,753 |
| 99204 Office E&M - New | Office | 62 | 62 | $110.58 | $6,856 |
| 99215 Office E&M - Established | Office | 54 | 47 | $132.94 | $7,179 |
| 95908 Electrical Nerve Conductivity | Office | 40 | 39 | $83.54 | $3,342 |
| 99205 Office E&M - New | Office | 35 | 35 | $162.91 | $5,702 |
| 95819 Neurologic | Office | 32 | 31 | $335.63 | $11K |
| 95910 Electrical Nerve Conductivity | Office | 28 | 28 | $124.85 | $3,496 |
| 95909 Electrical Nerve Conductivity | Office | 20 | 19 | $83.58 | $1,672 |
| 95911 Electrical Nerve Conductivity | Office | 11 | 11 | $145.14 | $1,597 |
By year: 2022 $237K for 15,808 services; 2023 $186K for 14,699 services; 2024 $178K for 13,403 services.
Medicare prescription drug claims, 2024
In 2024, the drug Donald Negroski prescribed most often to Medicare patients was Baclofen, with 353 prescriptions and refills. In total Donald Negroski wrote 3,896 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 353 | 735 | 97 | $9,286 |
| Dalfampridine Er Dalfampridine | 201 | 287 | 29 | $92K |
| Gabapentin Generic | 200 | 483 | 61 | $6,815 |
| Teriflunomide Generic | 167 | 189 | 19 | $240K |
| Tizanidine Hcl Generic | 132 | 272 | 35 | $1,922 |
| Carbidopa-Levodopa Carbidopa/Levodopa | 117 | 262 | 31 | $2,273 |
| Copaxone Glatiramer Acetate | 109 | 131 | Under 11 | $778K |
| Aubagio Teriflunomide | 104 | 104 | 11 | $966K |
| Kesimpta Pen Ofatumumab | 101 | 101 | 11 | $861K |
| Pregabalin Generic | 99 | 169 | 18 | $3,451 |
| Duloxetine Hcl Generic | 95 | 248 | 25 | $2,058 |
| Levetiracetam Generic | 83 | 193 | 20 | $2,501 |
| Donepezil Hcl Generic | 82 | 145 | 18 | $604 |
| Clonazepam Generic | 71 | 111 | 18 | $845 |
| Primidone Generic | 70 | 196 | 17 | $1,151 |
Brand drugs: 920 claims; generic drugs: 2,976 claims; opioid claims: 23.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Donald Negroski $236K ($236K in general payments such as food, travel and fees) from 19 companies. The largest payer was EMD Serono, Inc. with $135K.
| Company | Payments | Amount |
|---|---|---|
| EMD Serono, Inc. MRK.DE | 62 | $135K |
| Biogen, Inc. BIIB | 27 | $27K |
| TG Therapeutics, Inc. TGTX | 23 | $26K |
| Alexion Pharmaceuticals, Inc. AZN | 18 | $17K |
| Merck Healthcare KGaA | 4 | $15K |
| Novartis Pharmaceuticals Corporation NVS | 15 | $11K |
| Vanda Pharmaceuticals Inc. VNDA | 5 | $3,492 |
| Abbvie Inc. ABBV | 11 | $250 |
| Genzyme Corporation SNY | 6 | $220 |
| Genentech USA, Inc. ROG.SW | 4 | $200 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.